Contract Research Solutions for Respiratory Diseases

Online Inquiry

First Name *

Last Name *

Business Email *

Phone

Company/Institution

Job Title

Services of Interest *

When do you expect your project to start?

Project Description

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Pulmonary Fibrosis Model Development Services

Inquiry

At Ace Therapeutics, we recognize the complexities of developing effective therapeutics for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases. The translational gap between bench research and clinical success often hinges on the quality and relevance of the preclinical data generated.

The Importance of Clinically Relevant Fibrosis Models

Pulmonary fibrosis is a heterogeneous disease with complex pathologies. Utilizing the appropriate preclinical model is critical for:

Validating novel therapeutic targets.
Assessing the anti-fibrotic efficacy of drug candidates.
Understanding pharmacokinetic and pharmacodynamic (PK/PD) relationships in a diseased lung environment.
Identifying potential biomarkers for clinical translation.

Our portfolio of models is designed to mimic various aspects of human disease, from acute inflammation to chronic, progressive fibrosis.

Our Pulmonary Fibrosis Model Portfolio

We offer expertise in a range of established and specialized models. The choice of model depends on the mechanism of action of your test article and the specific endpoint you wish to investigate.

Model Type	Species	Induction Method	Key Applications
Chemically Induced	Mouse, Rat	Intratracheal (I.T.), Intranasal (I.N.), or Oropharyngeal aspiration of Bleomycin	Standard efficacy screening for anti-inflammatory and anti-fibrotic compounds.
Silica-Induced	Mouse, Rat	Inhalation or Intratracheal instillation of crystalline silica	Modeling chronic, progressive fibrosis with persistent inflammation (silicosis model).
Radiation-Induced	Mouse	Whole-thorax irradiation	Studying fibrosis as a late-stage effect of radiation injury.
Transgenic/Genetic	Mouse	Spontaneous mutation (e.g., TGF-α overexpression) or genetic knock-in	Investigating specific molecular pathways (e.g., TGF-β signaling) in fibrosis development.
Humanized Models	Mouse	Engraftment of human cells/tissues + fibrotic challenge	Evaluating immune cell or fibroblast-targeted therapeutics in a human-like context.

Tailored Services to Support Your Pipeline

Beyond model induction, our core strength lies in our comprehensive downstream service capabilities. We work with you to design a study that aligns with your developmental stage and regulatory requirements.

Model Development & Customization

Protocol Optimization: We can adjust dosage regimens, routes of administration, and time courses to suit your compound's properties.
Sex as a Biological Variable (SABV): Studies can be designed to include both male and female animals to investigate potential differences in disease progression and treatment response.
Disease-Stage Intervention: Evaluate your therapeutic in a preventive (prophylactic), therapeutic (early intervention), or treatment (established fibrosis) setting.

Pharmacological Efficacy Assessment

Bronchoalveolar Lavage Fluid (BALF) Analysis:
- Inflammatory cell counts and differentials.
- Total protein content (as a marker of vascular leakage).
- Cytokine/Chemokine profiling (e.g., TGF-β1, TNF-α, IL-6) via multiplex assays or ELISA.
Histopathology & Imaging:
- H&E staining for general morphology and inflammation.
- Masson's Trichrome and Picro-Sirius Red staining for collagen deposition and fibrosis extent.
- Ashcroft scoring and quantitative image analysis (e.g., fibrotic area %) by board-certified pathologists.
- Immunohistochemistry (IHC) for specific markers like α-SMA (myofibroblasts), Collagen I, Fibronectin, and F4/80 (macrophages).

Biochemical & Molecular Analyses

Hydroxyproline Assay: Quantitative measurement of collagen content in lung tissue.
Gene Expression (qPCR): Profiling of fibrotic and inflammatory genes (e.g., Col1a1, Acta2, Tgfb1, Mmp/Timp).
Protein Biomarker Analysis: Detection of soluble mediators of fibrosis in tissue homogenates or plasma.

Pharmacokinetic & Pharmacodynamic (PK/PD) Integration

We can integrate PK sampling into your efficacy study to help establish exposure-response relationships. This aids in understanding the concentration of your drug required at the site of action to achieve an anti-fibrotic effect.

Why Collaborate with Ace Therapeutics for Your Pulmonary Fibrosis Research?

Deep Respiratory Expertise: Our scientific team possesses focused experience in respiratory disease pathology and pharmacology, ensuring your study is designed with biological relevance in mind.
Customizable Approach: We avoid a one-size-fits-all methodology. Each study protocol is developed collaboratively to address your unique hypothesis and compound characteristics.
High-Quality Data: We are committed to delivering comprehensive study reports with raw data, detailed methods, and interpreted results to support your internal decision-making and regulatory submissions.
Focus on Rigor & Reproducibility: Our standard operating procedures and quality control measures are designed to minimize variability and ensure consistent, reliable outcomes.

Start Your Preclinical Journey with Confidence

Selecting the right partner for preclinical efficacy studies is a critical step in respiratory drug development. At Ace Therapeutics, we are dedicated to providing the scientific expertise, operational excellence, and customizable models you need to advance your pulmonary fibrosis program with confidence.

Frequently Asked Questions (FAQs)

What is the standard model for pulmonary fibrosis research, and do you offer it?

The bleomycin-induced model is the most widely used and best-characterized preclinical model for pulmonary fibrosis. Yes, we routinely perform bleomycin challenges in both mice and rats via various routes (I.T., I.N., systemic). We can tailor the dosing schedule and duration to match your needs.

Can you test a compound in a model of established fibrosis, rather than a preventative model?

Yes. We strongly recommend efficacy studies in a therapeutic mode to better mimic the clinical scenario, where patients already have established disease. We typically initiate treatment 7–10 days post-bleomycin instillation, after the acute inflammatory phase has peaked and fibrogenesis is underway.

What endpoints are most critical for demonstrating anti-fibrotic efficacy?

While a single endpoint can be suggestive, a robust demonstration of efficacy typically requires a combination of endpoints. This usually includes:

Histological assessment (qualitative scoring and quantitative morphometry of collagen deposition).
Biochemical quantification of collagen (hydroxyproline assay).
BALF analysis to assess any accompanying inflammatory changes.

We can help you select the most appropriate endpoints based on your mechanism of action.

How do you ensure the reproducibility of the fibrotic response?

Reproducibility is key. We achieve this through:

Strict adherence to standardized protocols for compound preparation and administration.
Use of animals from specific pathogen-free (SPF) colonies with defined weight and age ranges.
Inclusion of appropriate vehicle and positive control groups in every study.
Blinded histological scoring to reduce observer bias.

Do you offer models beyond the standard mouse/rat bleomycin?

Absolutely. In addition to chemically induced models, we have expertise in silica-induced chronic fibrosis and radiation-induced fibrosis models. We also have the capability to work with genetically modified mouse models to explore specific mechanistic pathways. Please contact us to discuss the feasibility of a specialized model for your target.